

C L A I M S

1. A venlafaxin containing coated tablet with controlled release, characterized in that it contains venlafaxin, or its salt with an inorganic or carboxylic acid, in amounts from 20 to 60 weight %, and a hydrophilic polymer in amounts from 30 up to 70 weight %, based on the weight of the core, in its core, and from 1 up to 3 weight % of a water-poorly permeable or impermeable polymer in its coating.
2. The coated tablet according to claim 1, characterized in that its total weight does not exceed 500 mg.
3. The coated tablet according to claim 1 or 2, characterized in that it contains a cellulose ester as the hydrophilic polymer in the core.
4. The coated tablet according to any of claims 1 to 3, characterized in that it contains an acrylic polymer as the water-poorly permeable polymer in the coating.
5. The coated tablet according to any of claims 1 to 4, characterized in that it contains 75 mg of the active substance, based on the venlafaxin base, from 100 to 200 mg of Methocel K 100M Premium EP in its core and from 3 to 10 mg of Eudragit L 30 D-55 in its coating.
6. The coated tablet according to any of the claims 1 to 4, characterized in that it contains 150 mg of the active substance, based on the venlafaxin base, from 150 to 300 mg of Methocel K 100M Premium EP in its core and from 3 to 10 mg of Eudragit L 30 D in its coating.
7. A method of production of the tablet according to claim 1, characterized in that a mixture of venlafaxin and a hydrophilic polymer is mixed in a homogenizing device, with optional subsequent addition of colloidal silicon dioxide along with magnesium stearate, after homogenizing the mixture is briquetted, subsequently the particle size of the tablet material is adjusted and compressing into tablets is carried, the tablets being coated with a suspension of the water-poorly permeable polymer, optionally along with talc and acetyl triethyl citrate.